Lakewood-Amedex Biotherapeutics Finalizes Redemption of Series C Convertible Preferred Stock

Lakewood-Amedex Biotherapeutics Completes Series C Stock Redemption

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT), a clinical-stage biotechnology company, announced on November 5, 2026, that it has successfully executed the redemption of all outstanding shares of its Series C Convertible Preferred Stock. This significant financial maneuver was executed under a redemption agreement dated November 2, 2026, in collaboration with Shakawe Capital LLC.

The total number of shares redeemed amounted to 127,097, which cost the company an aggregate cash redemption price of $1,270,970. This sum was financed using available cash reserves, showcasing the firm’s strong liquidity position. With this completion, Lakewood-Amedex no longer holds any shares of Series C Preferred Stock. Importantly, this action will not lead to any additional shares of common stock being issued upon conversion of the Series C Preferred Stock.

The completion of this redemption significantly simplifies Lakewood-Amedex's capital structure, removing potential dilution from the conversion of Series C shares. According to Dr. Kelvin Cooper, CEO of Lakewood-Amedex, this decision eliminates the financial limitations previously associated with the preferred stock, thereby allowing greater financial agility as the company advances its development programs.

Lakewood-Amedex is pioneering a new category of rapid-acting, broad-spectrum antimicrobials known as the Bisphosphocin® class. These antimicrobials are specifically designed to combat infectious diseases and address the growing threat posed by antibiotic-resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE).

This strategic move is seen as a positive step towards enhancing the company's financial sustainability. By clearing the preferred stock from its balance sheet, Lakewood-Amedex is well-positioned to focus on its core mission: the development of innovative therapeutic options that can potentially make a difference in the fight against infectious diseases. As the biotechnology firm progresses, it will seek to secure further financing in support of its development initiatives and future clinical trials, underscoring their commitment to bringing novel and effective treatments to market.

For more information about Lakewood-Amedex and its vision, one can visit their official website at Lakewood-Amedex.

Lakewood-Amedex invites stakeholders to stay tuned for updates regarding their clinical development plans and anticipated trials. The company is optimistic about future endeavors, emphasizing the potential benefits and efficacy of its Bisphosphocin® platform and product candidates. Should any uncertainties arise, the company will inform its investors, adhering to compliance as outlined in the Private Securities Litigation Reform Act of 1995.

For inquiries regarding company details post-redemption or any future developments, stakeholders are encouraged to reach out to Tiberend Strategic Advisors, who handle both media and investor relations for Lakewood-Amedex.

Conclusion

This redemption marks a pivotal moment in Lakewood-Amedex's journey, yielding a streamlined capital framework that fortifies its focus on innovation in biotechnology. The ongoing efforts to address the challenges of antibiotic resistance speak volumes about the company's commitment to public health and research. Stakeholders and the medical community alike are encouraged to follow closely as Lakewood-Amedex continues its pathway to success in the biopharmaceutical arena.